Ovid Therapeutics Inc.
OVID
$0.3383
-$0.0117-3.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 44.39% | 113.30% | 186.29% | 284.12% | -73.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.39% | 113.30% | 186.29% | 284.12% | -73.92% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 44.39% | 113.30% | 186.29% | 284.12% | -73.92% |
| SG&A Expenses | -9.77% | -15.31% | -13.48% | -13.25% | -13.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.80% | 24.81% | 20.91% | 8.33% | -1.35% |
| Operating Income | -6.54% | -24.32% | -20.30% | -7.71% | -0.59% |
| Income Before Tax | 49.50% | 33.02% | 39.58% | 1.44% | 3.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.50% | 33.02% | 39.58% | 1.44% | 3.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.50% | 33.02% | 39.58% | 1.44% | 3.38% |
| EBIT | -6.54% | -24.32% | -20.30% | -7.71% | -0.59% |
| EBITDA | -6.53% | -24.64% | -20.64% | -7.84% | -0.50% |
| EPS Basic | 49.41% | 34.80% | 41.23% | 3.48% | 5.30% |
| Normalized Basic EPS | 51.95% | 36.66% | 43.07% | 5.08% | 5.99% |
| EPS Diluted | 48.78% | 33.56% | 40.20% | 2.00% | 4.49% |
| Normalized Diluted EPS | 51.86% | 36.57% | 42.98% | 5.08% | 5.99% |
| Average Basic Shares Outstanding | 0.46% | 0.42% | 0.36% | 0.27% | 0.25% |
| Average Diluted Shares Outstanding | 0.56% | 0.52% | 0.46% | 0.27% | 0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |